Cadrenal Therapeutics stockholders approve 323,542-share increase to equity incentive plan
At its September 24, 2026 annual meeting, Cadrenal Therapeutics stockholders approved Amendment No. 2, which raises the share reserve under the 2022 Successor Equity Incentive Plan to 1,000,000 shares. They also approved issuing up to 960,000 shares on exercise of Series C-1 warrants from a private placement that closed July 1, 2026. The added share capacity and potential warrant shares could dilute existing holders' stakes.
Key points
- Plan amendment increases the 2022 Plan share reserve by 323,542 shares to 1,000,000 shares; 694,746 votes for and 352,409 against.
- Stockholders approved issuing up to 960,000 shares on exercise of Series C-1 warrants; 1,011,206 votes for and 34,449 against.
- Quang X. Pham was re-elected as a Class I director to serve until the 2029 annual meeting, with 1,039,666 votes for and 14,342 withheld.
- WithumSmith+Brown, P.C. was ratified as independent auditor for the fiscal year ending December 31, 2026, with 2,110,693 votes for and 39,121 against.
The filing
Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.